Genmab to raise USD 500 million and expand investor group in US offering
Genmab's upcoming IPO in the US is partly a way of involving more investors with insight in the biotech industry, says Senior Analyst in Sydbank, Søren Løntoft Hansen. But the offering will also reinforce the company's capital reserves that could potentially increase to approximately DKK 10 billion.
af IDA LØJMAND
Last week, Danish biotech company Genmab proposed a public offering of its American Depositary Shares (ADSs) and applied for listing on Nasdaq in the US.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
